GPO-VIR S7

GPO-VIR S7 is a pediatric fixed-dose combination (FDC) antiretroviral therapy developed by the Thai Government Pharmaceutical Organization (GPO) in collaboration with the National Institute of Allergy and Infectious Diseases (NIAID). It contains three active ingredients: stavudine (7 mg), lamivudine (30 mg), and nevirapine (50 mg) formulated as an orange-flavored chewable tablet. This combination therapy is designed to treat HIV infection in children by targeting the HIV-1 reverse transcriptase enzyme. Stavudine and lamivudine are nucleoside reverse transcriptase inhibitors (NRTIs) that act as chain terminators during viral DNA synthesis, while nevirapine is a non-nucleoside reverse transcriptase inhibitor (NNRTI) that binds to an allosteric site on the enzyme to inhibit its activity. The chewable formulation was specifically developed to improve adherence and dosing accuracy in pediatric populations, particularly in resource-limited settings. It has been evaluated in Phase I/II pharmacokinetic studies (such as IMPAACT P1056) to ensure bioequivalence and safety compared to individual liquid formulations.

Brand names

GPO-VIR S7GPO-VIR Pediatric

Other names

lamivudine + nevirapine + stavudine3TC + NVP + d4Tstavudine, lamivudine, and nevirapine fixed-dose tablet